IL263291B2 - Diet controlled expression of nucleic acid encoding cas9 nuclease and its uses - Google Patents

Diet controlled expression of nucleic acid encoding cas9 nuclease and its uses

Info

Publication number
IL263291B2
IL263291B2 IL263291A IL26329118A IL263291B2 IL 263291 B2 IL263291 B2 IL 263291B2 IL 263291 A IL263291 A IL 263291A IL 26329118 A IL26329118 A IL 26329118A IL 263291 B2 IL263291 B2 IL 263291B2
Authority
IL
Israel
Prior art keywords
nucleic acid
pharmaceutical composition
expression
disease
cell
Prior art date
Application number
IL263291A
Other languages
English (en)
Hebrew (he)
Other versions
IL263291B1 (en
IL263291A (en
Original Assignee
Inst Nat Sante Rech Med
Icm Inst Du Cerveau Et De La Moelle Epiniere
Centre Nat Rech Scient
Univ Sorbonne
Commissariat A Lenergie Atomique Et Aux Energies Alternatives Cea
Hopitaux Paris Assist Publique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Icm Inst Du Cerveau Et De La Moelle Epiniere, Centre Nat Rech Scient, Univ Sorbonne, Commissariat A Lenergie Atomique Et Aux Energies Alternatives Cea, Hopitaux Paris Assist Publique filed Critical Inst Nat Sante Rech Med
Publication of IL263291A publication Critical patent/IL263291A/en
Publication of IL263291B1 publication Critical patent/IL263291B1/en
Publication of IL263291B2 publication Critical patent/IL263291B2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102Mutagenizing nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/001Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
IL263291A 2016-06-03 2018-11-26 Diet controlled expression of nucleic acid encoding cas9 nuclease and its uses IL263291B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16172964 2016-06-03
PCT/EP2017/063549 WO2017207797A1 (en) 2016-06-03 2017-06-02 Diet controlled expression of a nucleic acid encoding cas9 nuclease and uses thereof

Publications (3)

Publication Number Publication Date
IL263291A IL263291A (en) 2018-12-31
IL263291B1 IL263291B1 (en) 2023-03-01
IL263291B2 true IL263291B2 (en) 2023-07-01

Family

ID=56148119

Family Applications (1)

Application Number Title Priority Date Filing Date
IL263291A IL263291B2 (en) 2016-06-03 2018-11-26 Diet controlled expression of nucleic acid encoding cas9 nuclease and its uses

Country Status (11)

Country Link
US (2) US20190185832A1 (enExample)
JP (2) JP7436145B2 (enExample)
KR (1) KR102317622B1 (enExample)
CN (2) CN116064534A (enExample)
AU (1) AU2017275769B2 (enExample)
BR (1) BR112018074930A2 (enExample)
CA (1) CA3025591A1 (enExample)
IL (1) IL263291B2 (enExample)
RU (1) RU2771383C2 (enExample)
SG (1) SG11201810772XA (enExample)
WO (1) WO2017207797A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3823995A4 (en) * 2018-08-01 2022-05-04 The Regents of the University of Colorado, a body corporate PROGRAMMABLE THERAPEUTIC FUSOGENE SECRETED GECTOSOME DESIGNER VESICLES FOR MACROMOLECULE RELEASE AND GENOME MODIFICATION
CN112442528B (zh) * 2019-08-30 2022-08-12 深圳华大基因股份有限公司 Loxhd1基因突变体及其应用
CN114058689B (zh) * 2020-07-30 2024-08-20 南京市妇幼保健院 一种基因突变检测试剂盒及其应用
CN119894540A (zh) * 2022-07-05 2025-04-25 营养治疗基因公司 人类t或nk细胞中转基因的受控表达用于细胞免疫疗法
WO2024100176A1 (en) * 2022-11-10 2024-05-16 Nutritheragene Controlled gene therapy of ocular diseases
CN116732043B (zh) * 2023-08-10 2023-10-17 四川省医学科学院·四川省人民医院 一种突变基因及其白内障筛查的用途与白内障筛查试剂盒

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013068096A1 (fr) * 2011-11-08 2013-05-16 Institut National De La Recherche Agronomique (Inra) Cassette d'expression inductible et ses utilisations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2713243T3 (es) * 2012-12-06 2019-05-20 Sigma Aldrich Co Llc Modificación y regulación del genoma basada en CRISPR
US20150098954A1 (en) * 2013-10-08 2015-04-09 Elwha Llc Compositions and Methods Related to CRISPR Targeting
EP3080261B1 (en) 2013-12-12 2019-05-22 The Broad Institute, Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders
KR20250068794A (ko) 2013-12-12 2025-05-16 더 브로드 인스티튜트, 인코퍼레이티드 게놈 편집을 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료적 응용

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013068096A1 (fr) * 2011-11-08 2013-05-16 Institut National De La Recherche Agronomique (Inra) Cassette d'expression inductible et ses utilisations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHAVEROUX ET AL,, IN VIVO IMAGING OF THE SPATIOTEMPORAL ACTIVITY OF THE EIF2A-ATF4 SIGNALING PATHWAY: INSIGHTS INTO STRESS AND RELATED DISORDERS, 28 April 2015 (2015-04-28) *

Also Published As

Publication number Publication date
IL263291B1 (en) 2023-03-01
BR112018074930A2 (pt) 2019-03-12
KR102317622B1 (ko) 2021-10-26
RU2018142174A (ru) 2020-07-10
US20190185832A1 (en) 2019-06-20
AU2017275769A1 (en) 2018-12-20
SG11201810772XA (en) 2018-12-28
CA3025591A1 (en) 2017-12-07
AU2017275769B2 (en) 2023-04-13
RU2771383C2 (ru) 2022-05-04
CN116064534A (zh) 2023-05-05
US20230313161A1 (en) 2023-10-05
JP2022133441A (ja) 2022-09-13
JP2019517262A (ja) 2019-06-24
KR20190031230A (ko) 2019-03-25
IL263291A (en) 2018-12-31
CN109906271A (zh) 2019-06-18
RU2018142174A3 (enExample) 2020-09-30
WO2017207797A1 (en) 2017-12-07
JP7436145B2 (ja) 2024-02-21

Similar Documents

Publication Publication Date Title
US20230313161A1 (en) Diet controlled expression of a nucleic acid encoding cas9 nuclease and uses thereof
US20230242899A1 (en) Methods and compositions for modulating a genome
US20240417757A1 (en) Methods and compositions for modulating a genome
US11492643B2 (en) Methods and compositions for treatment of a genetic condition
AU2017336100B2 (en) Non-human animals having a hexanucleotide repeat expansion in a C9ORF72 locus
JP2020510439A (ja) シトシンからグアニンへの塩基編集因子
US20250057780A1 (en) Nanoparticles and methods of production for the encapsulation of nucleic acids
US20240327812A1 (en) Fusion effector proteins and uses thereof
EP3464574A1 (en) Diet controlled expression of a nucleic acid encoding cas9 nuclease and uses thereof
US20250066772A1 (en) Method of modulating vegf and uses thereof
US20220411826A1 (en) Co-opting regulatory bypass repair of genetic diseases
WO2025106739A1 (en) Compositions and methods for epigenetic regulation of htt expression
WO2025212757A2 (en) Cas enabled targeted transposition
TW202440938A (zh) 用於抑制微管解聚蛋白2(stmn2)轉錄物中異常剪接的基因編輯方法
JP2025525389A (ja) Ciita発現のエピジェネティック調節のための組成物及び方法
EP4544057A1 (en) Compositions and methods for epigenetic regulation of trac expression
HK1210502B (en) Methods and compositions for treatment of a genetic condition